TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular...
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide...
Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell...
Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE ® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R 2...
Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations...
Genmab A/S (NASDAQ:GMAB) reported first-quarter 2026 results highlighting revenue growth, expanding proprietary product sales, and continued investment in its late-stage pipeline, while maintaining profitability....
Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in...
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory...
Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review ...